TELFORD, Pennsylvania, June 22, 2026
Draeger, Inc., the U.S. headquarters of global medical technology leader Dräger, has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the latest Evita V800 Software 3.10 upgrade, introducing advanced ventilation capabilities designed to support the treatment of critically ill patients with severe pulmonary diseases, including Acute Respiratory Distress Syndrome (ARDS). The regulatory clearance marks another important milestone in Dräger’s long-standing commitment to advancing respiratory care technology and improving clinical decision-making in intensive care environments. The newly approved software enhancements provide clinicians with expanded tools for optimizing ventilation strategies, reducing the risk of ventilator-associated complications, and improving patient management. As hospitals continue to focus on precision respiratory support and lung-protective ventilation approaches, the updated Evita V800 platform is expected to strengthen critical care capabilities while supporting evidence-based treatment protocols for patients requiring mechanical ventilation.
New Ventilation Features Enhance ARDS Patient Management
The FDA-cleared Software 3.10 release introduces several advanced features specifically designed to improve ventilation management in patients with complex respiratory conditions. One of the most notable additions is decelerating flow during volume control ventilation, which allows clinicians to better match inspiratory flow delivery with individual patient demand while maintaining adherence to established ARDSnet lung-protective ventilation recommendations. This enhancement can help optimize patient comfort and ventilator synchrony while supporting safer ventilation practices.
The updated software also incorporates guidance maps for low and high Positive End-Expiratory Pressure (PEEP) and Fraction of Inspired Oxygen (FiO₂) settings, providing clinicians with visual decision-support tools to help determine optimal ventilatory parameters. By simplifying complex respiratory management decisions, these features aim to improve consistency of care and support individualized treatment strategies in intensive care settings.
Advanced Monitoring Tools Support Lung-Protective Ventilation
Advertisement
Another significant advancement included in the software update is the addition of driving pressure calculations and semi-automated static compliance measurements, two important metrics increasingly recognized for their role in protecting lung tissue during mechanical ventilation. Driving pressure has emerged as a key parameter associated with patient outcomes in ARDS, while static compliance measurements help clinicians assess lung mechanics and optimize ventilator settings. By integrating these capabilities directly into the Evita V800 platform, Dräger provides healthcare professionals with enhanced visibility into respiratory function and enables more informed management of inspiratory settings.
These tools may contribute to reducing the risk of ventilator-induced lung injury (VILI), one of the most significant complications associated with prolonged mechanical ventilation. The combination of advanced monitoring and decision-support capabilities reflects the growing trend toward intelligent ventilator technologies capable of delivering more personalized respiratory care.
Strengthening Critical Care Innovation Through Respiratory Technology
The FDA clearance reinforces Dräger’s position as a global leader in respiratory care and mechanical ventilation technologies. With more than a century of innovation in medical technology and a presence in over 190 countries, the company continues to invest heavily in research and development aimed at improving outcomes for critically ill patients. Company leadership emphasized that the Evita V800 enhancements reflect Dräger’s ongoing dedication to supporting healthcare professionals with innovative tools that improve efficiency, safety, and patient care quality.
As healthcare systems worldwide increasingly adopt advanced digital and data-driven technologies in critical care, intelligent ventilation platforms such as the Evita V800 are expected to play an increasingly important role in managing severe respiratory diseases. The newly cleared software update provides clinicians with additional capabilities to deliver evidence-based respiratory support while helping hospitals advance their critical care standards and improve outcomes for patients requiring mechanical ventilation.
Source: Draeger press release
